(VIANEWS) – AMSC (AMSC.OL), KID (KID.OL), VISTIN PHARMA (VISTN.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. AMSC (AMSC.OL)
1395% sales growth and 8.21% return on equity
AMSC ASA, through its subsidiaries, invests in maritime assets and companies in the United States. It operates one international subsea construction vessel. The company was formerly known as American Shipping Company ASA and changed its name to AMSC ASA in October 2022. AMSC ASA was incorporated in 2005 and is headquartered in Lysaker, Norway.
Earnings Per Share
As for profitability, AMSC has a trailing twelve months EPS of kr2.85.
PE Ratio
AMSC has a trailing twelve months price to earnings ratio of 9.51. Meaning, the purchaser of the share is investing kr9.51 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.21%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 30, 2023, the estimated forward annual dividend rate is 5.28 and the estimated forward annual dividend yield is 12.8%.
Moving Average
AMSC’s value is way under its 50-day moving average of kr39.16 and way below its 200-day moving average of kr41.54.
More news about AMSC.
2. KID (KID.OL)
7.5% sales growth and 29.84% return on equity
Kid ASA, together with its subsidiaries, operates as a home textile retailer in Norway, Sweden, Finland, and Estonia. It designs, sources, markets, and sells a range of home and interior products, including textiles, curtains, bed linens, home accessories, decorations, furniture, and other interior products through retail stores and online platforms. The company provides its products under the Kid, Hemtex, Dekosol, Nordun, and Premium Collection brands. It also offers logistics services. The company was formerly known as Nordisk Tekstil Holding AS and changed its name to Kid ASA. Kid ASA was founded in 1937 and is headquartered in Lier, Norway.
Earnings Per Share
As for profitability, KID has a trailing twelve months EPS of kr8.94.
PE Ratio
KID has a trailing twelve months price to earnings ratio of 17.02. Meaning, the purchaser of the share is investing kr17.02 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.84%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 30% and 9.9%, respectively.
Moving Average
KID’s worth is higher than its 50-day moving average of kr145.04 and above its 200-day moving average of kr139.68.
More news about KID.
3. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 23.89% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.54.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.86. Meaning, the purchaser of the share is investing kr17.86 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.89%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Nov 6, 2024, the estimated forward annual dividend rate is 1.75 and the estimated forward annual dividend yield is 6.27%.
Volume
Today’s last reported volume for VISTIN PHARMA is 22168 which is 38.39% below its average volume of 35985.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the present quarter and 6.6% for the next.
More news about VISTIN PHARMA.
